Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

QR Code

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

Frank Weinberg, Shirish GadgeelDivision of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USAAbstract: Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cyt...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Weinberg F, Gadgeel S
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	NSCLC immunotherapy chemotherapy clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/449832ce898049848b3bf1a0e69f940c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
par: Zheng Yuan, et autres
Publié: (2021)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
par: Tsuchiya-Kawano Y, et autres
Publié: (2021)

Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis
par: Han Feng, et autres
Publié: (2021)

Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
par: Mudad R, et autres
Publié: (2017)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
par: Giustini N, et autres
Publié: (2021)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
par: Diego Kauffmann-Guerrero, et autres
Publié: (2021)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
par: Chun-Hua Zhou, et autres
Publié: (2021)

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
par: Ting Yoon Kwan, et autres
Publié: (2021)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
par: Schuette W, et autres
Publié: (2017)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
par: Fajun Pei, et autres
Publié: (2021)

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
par: Mitsuro Kanda, et autres
Publié: (2021)

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
par: Zhihui Zhang, et autres
Publié: (2021)

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
par: Alessio Bruni, et autres
Publié: (2021)

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
par: Alessio Bruni, et autres
Publié: (2021)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
par: Alimohammadi R, et autres
Publié: (2020)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
par: Huiqiu ZHANG, et autres
Publié: (2021)

Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
par: Vicky Mai, et autres
Publié: (2021)

Treatment of advanced small cell lung cancer. Clinical case and literature review
par: Konstantin V. Menshikov, et autres
Publié: (2021)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
par: Ze-Rui Zhao, et autres
Publié: (2021)

Small cell lung cancer transformation during antitumor therapies: A systematic review
par: Chai Xing, et autres
Publié: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
par: Zago G, et autres
Publié: (2016)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
par: Tobias Dechow, et autres
Publié: (2021)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
par: Florian Gebauer, et autres
Publié: (2021)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
par: Al-Keilani MS, et autres
Publié: (2018)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
par: Qiao Liu, et autres
Publié: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
par: Qiao Liu, et autres
Publié: (2021)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
par: Minami S, et autres
Publié: (2016)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
par: Luis de la Cruz-Merino, et autres
Publié: (2021)

Chemotherapy-Induced Hepatotoxicity in HIV Patients
par: Silvia Bressan, et autres
Publié: (2021)

A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study
par: An-Wen Xiong, et autres
Publié: (2021)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
par: Chengming Liu, et autres
Publié: (2021)

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
par: Lundstrom K
Publié: (2018)

PLoS clinical trials
Publié: (2006)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
par: Jie Zhang PhD, et autres
Publié: (2021)

Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy
par: Dong Hyun Lee, et autres
Publié: (2021)

Clinical trials in Irkutsk Scientific Center of Surgery and Traumatology: results and prospects
par: K. A. Apartsin, et autres
Publié: (2016)

Applied clinical trials
Publié: (1992)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
par: Yang Teng, et autres
Publié: (2021)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
par: Youwen Zhu, et autres
Publié: (2021)

Contemporary clinical trials
Publié: (2005)